BioCentury
ARTICLE | Company News

Biotica, Buck Institute for Research on Aging deal

September 19, 2011 7:00 AM UTC

Biotica and the not-for-profit institute partnered to discover and develop therapies using rapamycin analogs and other polyketides to treat age-related diseases, including Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD). Under the three-year deal, the institute is responsible for "all aspects of therapeutic biology" while Biotica will provide its polyketide libraries and apply its polyketide engineering technology. The partners will share rights to IP developed under the deal. ...